Navigation Links
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Date:11/10/2008


First in class drug illustrates early signal of transport of key amyloid

marker from brain

TSX Exchange Symbol: RVX

CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found that treatment with RVX-208 resulted in a positive trend on an important marker of cognitive function and Alzheimer's disease, Amyloid-beta40 is an important constituent of amyloid plaques in the brains of Alzheimer's patients. The analysis of the plasma markers for Alzheimer's disease was performed by Dr. D. Larry Sparks, Senior Scientist and Head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Arizona.

The Phase 1a trial, a double-blind, dose-escalation, placebo-controlled trial enrolled 24 subjects in three separate dosing cohorts for a period of one week: 6 received placebo, and 6 received 2mg/kg per day, 6 received 3mg/kg per day and 6 received 8 mg/kg per day of RVX-208. Plasma levels of A-beta (A-beta40) were measured on day 1 and 7. A 12-14 percent increase in plasma A-beta40 levels was observed at the highest dose of RVX-208 after 7 days of dosing. Based on the study hypothesis these results trended towards significance versus placebo, even with the minimal number of study subjects.

Emerging evidence from large epidemiology studies such as the Harvard Women's Study, the Honolulu-Asia Aging Study and the Whitehall II study continue to build support for the relationship between poor HDL and ApoA-I levels and decreased cognitive function and Alzheimer's disease. Dr. Sparks's investigation of elective statin use and fractionated cholesterol levels in the ADAPT cohort has identified a significant relationship between elevated HDL levels and better performance on the Mini Mental State
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. International Steering Committee for RVX-208 IVUS Trial Formed
2. Phase 1b/2a Program Commences for RVX-208
3. Industry Leaders Select Resverlogixs RVX-208
4. Dosing for RVX-208 Phase 1a Clinical Study Completed
5. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
6. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
7. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
10. New Study Shares Best Practices in Biopharma Public Relations
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Va., Oct. 16 Varian Medical,Systems (NYSE: ... version of its market-leading,VariSeed(TM) brachytherapy seed planning ... allow greater visibility of the,treatment. "The ... the positions of,individual seeds in permanent seed ...
... Ranked 11th of the ,200 Best Small Companies In ... Inc.,(Nasdaq: ABAX ), a medical products company manufacturing ... chairman and chief executive officer, was named "Entrepreneur of,the ... issue. Also in that,issue, Abaxis was ranked eleventh of ...
... Novartis Takes Top Spot, Previously Held by GlaxoSmithKline ... 16 Thomson,Scientific, part of The Thomson Corporation ... of information solutions to the worldwide research and,business ... recent,quarterly review of scientific literature on drugs and ...
Cached Biology Technology:Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... for Cancer Research applauds President Obama,s nomination of Francis ... of the National Institutes of Health (NIH). ... said Tyler Jacks, Ph.D., president of the American Association ... Genome Research Institute and the Human Genome Project has ...
... Blacksburg, Va. -- Four researchers at the Virginia Bioinformatics ... the Wake Forest University School of Medicine are advocating ... approach to cancer. This approach could result in the ... well as potential new drug targets to help combat ...
... evidence for ice-free summers with intermittent winter sea ice in ... of greenhouse conditions - gives a glimpse of how the ... Records of past environmental change in the Arctic should help ... 100 and 65 million years ago leading up to the ...
Cached Biology News:Systems biology recommended as a clinical approach to cancer 2Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 3
... sizing single-stranded RNA ranging from 0.5 kb to 10 ... consists of nine bands in even increments (0.5 1 ... to simplify size estimation. The 1.5 kb band is ... and identification of RNA bands on the gel. All ...
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: